Skip to main content

Advertisement

Springer Nature Link
Log in

Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Cancer remains a global health problem and approximately 1.7 million new cancer cases are diagnosed every year worldwide. Although diverse molecules are currently being explored as targets for cancer therapy the tumor treatment and therapy is highly tricky. Secondary messengers are important for hormone-mediated signaling pathway. Cyclic AMP (cAMP), a secondary messenger responsible for various physiological processes regulates cell metabolism by activating Protein kinase A (PKA) and by targeting exchange protein directly activated by cAMP (EPAC). EPAC is present in two isoforms EPAC1 and EPAC2, which exhibit different tissue distribution and is involved in GDP/GTP exchange along with activating Rap1- and Rap2-mediated signaling pathways. EPAC is also known for its dual role in cancer as pro- and anti-proliferative in addition to metastasis. Results after perturbing EPAC activity suggests its involvement in cancer cell migration, proliferation, and cytoskeleton remodeling which makes it a potential therapeutic target for cancer treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
€32.70 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Finland)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics

  2. http://www.who.int/mediacentre/factsheets/fs297/en/

  3. Yan K, Gao LN, Cui YL, Zhang Y, Zhou X (2016) The cyclic AMP signaling pathway: exploring targets for successful drug discovery (Review). Mol Med Rep 13(5):3715–3723

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Hanoune Jand Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145–174

    Article  Google Scholar 

  5. Conti M, Beavo JA (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511

    Article  PubMed  CAS  Google Scholar 

  6. Mc Cahill AC, Huston E, Li X, Houslay MD (2008) PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb Exp Pharmacol 186:125–166

    Article  CAS  Google Scholar 

  7. Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91–100

    Article  PubMed  CAS  Google Scholar 

  8. Keravis T, Lugnier C (2010) Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 16:1114–1125

    Article  PubMed  CAS  Google Scholar 

  9. Bacallao K, Monje PV (2013) Opposing roles of PKA and EPAC in cAMP-dependent regulation of schwann cell proliferation and differentiation. PLoS ONE 8(12):e82354

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM et al (1998) EPAC is a Rap1 guanine nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474–477

    Article  PubMed  CAS  Google Scholar 

  11. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM (1998) A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275–2279

    Article  PubMed  CAS  Google Scholar 

  12. Sehrawat S, Cullere X, Patel S, Italiano J Jr, Mayadas TN (2008) Role of EPAC1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function. Mol Biol Cell 19:1261–1270

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Niimura M, Miki T, Shibasaki T, Fujimoto W, Iwanaga T, Seino S (2009) Critical role of the N-terminal cyclic AMP-binding domain of EPAC2 in its subcellular localization and function. J Cell Physiol 219:652–658

    Article  PubMed  CAS  Google Scholar 

  14. Qiao J, Mei FC, Popov VL, Vergara LA, Cheng X (2002) Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP. J Biol Chem 277:26581–26586

    Article  PubMed  CAS  Google Scholar 

  15. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL (2003) Cyclic AMP induces integrin-mediated cell adhesion through EPAC and Rap1 upon stimulation of the beta 2adrenergic receptor. J Cell Biol 160:487–493

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Gupta M, Yarwood SJ (2005) MAP1A light chain 2 interacts with exchange protein activated by cyclic AMP 1 (EPAC1) to enhance Rap1 GTPase activity and cell adhesion. J Biol Chem 280:8109–8116

    Article  PubMed  CAS  Google Scholar 

  17. Lorenowicz MJ, van Gils J, de Boer M, Hordijk PL, Fernandez-Borja M (2006) EPAC1-Rap1 signaling regulates monocyte adhesion and chemotaxis. J Leukoc Biol 80(6):1542–1552

    Article  PubMed  CAS  Google Scholar 

  18. Gloerich M, Ponsioen B, Vliem MJ, Zhang Z, Zhao J, Kooistra MR, Price LS, Ritsma L, Zwartkruis FJ, Rehmann H, Jalink K, Bos JL (2010) Spatial regulation of cyclic AMP-EPAC1 signaling in cell adhesion by ERM proteins. Mol Cell Biol 30(22):5421–5431

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Enserink JM1, Price LS, Methi T, Mahic M, Sonnenberg A, Bos JL, Taskén K (2004). The cAMP-EPAC-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J Biol Chem. 279(43):44889–44896.

    Article  PubMed  CAS  Google Scholar 

  20. Kooistra MR, Corada M, Dejana E, Bos JL (2005) EPAC1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 579(22):4966–4972

    Article  PubMed  CAS  Google Scholar 

  21. Mei FC, Cheng XD (2005). Interplay between exchange protein directly activated by cAMP (EPAC) and microtubule cytoskeleton. Mol Biosyst 1:325–331

    Article  PubMed  CAS  Google Scholar 

  22. Birukova AA, Zagranichnaya T, Fu P, Alekseeva E, Chen W, Jacobson JR, Birukov KG (2007) Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and EPAC1/ Rap1-dependent Rac activation. Exp Cell Res 313:2504–2520

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Birukova AA, Zagranichnaya T, Alekseeva E, Bokoch GM, Birukov KG (2008) EPAC/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J Cell Physiol 215:715–724

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Mani BK, Chuang JC, Kjalarsdottir L, Sakata I, Walker AK, Kuperman A, Osborne-Lawrence S, Repa JJ, Zigman JM (2014) Role of calcium and EPAC in norepinephrine-induced ghrelin secretion. Endocrinology 155(1):98–107

    Article  PubMed  CAS  Google Scholar 

  25. Islam D, Zhang N, Wang P, Li H, Brubaker PL, Gaisano HY, Wang Q, Jin T (2009) EPAC is involved in cAMP-stimulated proglucagon expression and hormone production but not hormone secretion in pancreatic alpha- and intestinal L-cell lines. Am J Physiol Endocrinol Metab 6(1):E174–E81

    Google Scholar 

  26. Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB (2014) Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS ONE 9(4):e94996

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Bos JL (2006) EPAC proteins: multi-purpose cAMP targets. Trends Biochem Sci 31(12):680–686

    Article  PubMed  CAS  Google Scholar 

  28. Li Y, Asuri S, Rebhun JF, Castro AF, Paranavitana NC, Quilliam LA (2006) The RAP1 guanine nucleotide exchange factor EPAC2 couples cyclic AMP and Ras signals at the plasma membrane. J Biol Chem 281:2506–2514

    Article  PubMed  CAS  Google Scholar 

  29. Li Y, Konings IBM, Zhao J, Price LS, de Heer E, Deen PMT (2008) Renal expression of exchange protein directly activated by cAMP (EPAC) 1 and 2. Am J Physiol Renal Physiol 295:F525–F533

    Article  PubMed  CAS  Google Scholar 

  30. Ponsioen B, Gloerich M, Ritsma L, Rehmann H, Bos JL, Jalink K (2009) Direct spatial control of EPAC1 by cyclic AMP. Mol Cell Biol 29:2521–2531

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Rehman H et al (2008) Structure of EPAC2 in complex with a cyclic AMP analogue and RAP1B. Nature 455:124–127

    Article  CAS  Google Scholar 

  32. Rehman H et al (2006) Structure of cyclic-AMP-responsive exchange factor EPAC2 in its auto-inhibited state. Nature 439:625–628

    Article  CAS  Google Scholar 

  33. Selvaratnam R (2012) The auto-inhibitory role of the EPAC hinge helix as mapped by NMR. PLoS ONE 7:e48707

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Selvaratnam R (2011) Mapping allostery through the covariance analysis of NMR chemical shifts. Proc Natl Acad USA 108:6133–6138

    Article  Google Scholar 

  35. Selvaratnam R (2012) The projection analysis of NMR chemical shifts reveals extended EPAC auto-inhibition determinants. Biophys J 102:630–639

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Das R (2009) Dynamically driven ligand selectivity in cyclic nucleotide binding domains. J Biol Chem 284:23682–23696

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Das R (2008) Entropy-driven cAMP-dependent allosteric control of inhibitory interactions in exchange proteins directly activated by cAMP. J Biol Chem 283:19691–19703

    Article  PubMed  CAS  Google Scholar 

  38. Boultan S (2014) Tapping the translation potential of cAMP signaling: molecular basis for selectivity in cAMP agonism and antagonism as revealed by NMR. Biochem Soc Trans 42:302–307

    Article  CAS  Google Scholar 

  39. Sprenger JU, Nikolaev VO (2013) Biophysical techniques for detection of cAMP and cGMP in living cells. Int J Mol Sci 14:8025–8046

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Onodera Y, Nam JM, Bissell MJ (2014) Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest 124(1):367–384

    Article  PubMed  CAS  Google Scholar 

  41. Kumar N, Gupta S, Dabral S, Singh S, Sehrawat S (2017) Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis. Mol Cell Biochem 430(1–2):115–125

    Article  PubMed  CAS  Google Scholar 

  42. Lim JA, Juhnn YS (2016) Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and EPAC pathways in human lung cancer cells. Exp Mol Med 48(1):e204

    Article  PubMed  PubMed Central  Google Scholar 

  43. Jeong MJ, Kim EJ, Cho EA, Ye SK, Kang GH, Juhnn YS (2013) cAMP signaling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via EPAC and p38 MAPK in lung cancer cells. FEBS Lett 587(9):1373–1378

    Article  PubMed  CAS  Google Scholar 

  44. Cho EA, Juhnn YS (2012). The cAMP signaling system inhibits the repair of γ-ray-induced DNA damage by promoting EPAC1-mediated proteasomal degradation of XRCC1 protein in human lung cancer cells. Biochem Biophys Res Commun 422(2):256–262

    Article  PubMed  CAS  Google Scholar 

  45. Pullamsetti SS, Banat GA, Schmall A, Szibor M, Pomagruk D, Hänze J, Kolosionek E, Wilhelm J, Braun T, Grimminger F, Seeger W, Schermuly RT, Savai R (2013) Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer with crosstalk with HIF. Oncogene 32(9):1121–1134

    Article  PubMed  CAS  Google Scholar 

  46. Grandoch M, López de Jesús M, Oude Weernink PA, Weber AA, Jakobs KH, Schmidt M (2009) B cell receptor-induced growth arrest and apoptosis in WEHI-231 immature B lymphoma cells involve cyclic AMP and EPAC proteins. Cell Signal 21(4):609–621

    Article  PubMed  CAS  Google Scholar 

  47. Park JY, Juhnn YS (2017) cAMP signaling increases histone deacetylase 8 expression via the EPAC2-Rap1A-Akt pathway in H1299 lung cancer cells. Exp Mol Med 49(2):e297

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M (1989) A ras related gene with transformation suppressor activity. Cell 56:77–84

    Article  PubMed  CAS  Google Scholar 

  49. De Falco V, Castellone MD, De vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M (2007) RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res 67:381–390

    Article  PubMed  CAS  Google Scholar 

  50. Itoh M, Nelson CM, Myers CA, Bissell MJ (2007) Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells. Cancer Res 67:4759–4766

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Baljinnyam E, Iwatsubo K, Kurotani R, Wang X, Ulucan C, Iwatsubo M, Lagunoff D, Ishikawa Y (2009) EPAC increases melanoma cell migration by a heparin sulfate related mechanism. Am J Physiol Cell Physiol 297(4):C802–C813

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Baljinnyam E, Umemura M, De Lorenzo MS, Xie LH, Nowycky M, Iwatsubo M, Chen S, Goydos JS, Iwatsubo K (2011) Gβγ subunits inhibit EPAC-induced melanoma cell migration. BMC Cancer 11:256

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Murray F, Zhang L, Zahno A, Anastasopulos A, Rassenti L, Kipps JT, Insel AP (2009) Protein kinase A and EPAC (exchange protein activated by cAMP) are pro-and anti-apoptotic mediators, respectively, in chronic lymphocytic leukemia. FASEB J 23:711–761

    Article  CAS  Google Scholar 

  54. Sassi Y, Lipskaia L, Vandecasteele G, Nikolaev VO, Hatem SN, Cohen Aubart F et al (2008) Multidrug resistance-associated protein 4 regulates cAMP dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest 118:2747–2757

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG et al (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979–6988

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Bröderdorf S, Zang S, Schaletzki Y, Grube M, Kroemer HK, Jedlitschky G (2014) cAMP regulates expression of the cyclic nucleotide transporter MRP4 (ABCC4) through the EPAC pathway. Pharmacogenet Genomics 24(10):522–526

    Article  PubMed  CAS  Google Scholar 

  57. Grandoch M, Rose A, ter Braak M, Jendrossek V, Rübben H, Fischer JW, Schmidt M, Weber AA (2009) EPAC inhibits migration and proliferation of human prostate carcinoma cells. Br J Cancer 101(12):2038–2042

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Misra UK, Pizzo SV (2009) EPAC1-induced cellular proliferation inprostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem 108(4):998–1011

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Misra UK, Pizzo SV (2013) Evidence for a pro-proliferative feedback loop in prostate cancer: the role of EPAC1 and COX-2-dependent pathways. PLoS ONE 8(4):e63150

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Fernández-Martínez AB, Carmena MJ, Bajo AM, Vacas E, Sánchez-Chapado M, Prieto JC (2015) VIP induces NF-kB1-nuclear localization through different signaling pathways in human tumour and non-tumour prostate cells. Cell Signal 27(2):236–244

    Article  PubMed  CAS  Google Scholar 

  61. Flacke JP, Flacke H, Appukuttan A, Palisaar RJ, Noldus J, Robinson BD, Reusch HP, Zippin JH, Ladilov Y (2015) Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells. J Biol Chem 288(5):3126–3135

    Article  CAS  Google Scholar 

  62. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR (2009). A novel interplay between EPAC/Rap1 and mitogen activated protein kinase 5/extracellular signal regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood 114(20):4592–4600

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Misra UK, Pizzo SV (2012) Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem 113(5):1488–1500

    PubMed  CAS  Google Scholar 

  64. Menon J, Doebele RC, Gomes S, Bevilacqua E, Reindl KM, Rosner MR (2012) A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0049893

    Article  PubMed  PubMed Central  Google Scholar 

  65. Parsa AT, Holland EC (2004) Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med 10:607–613

    Article  PubMed  CAS  Google Scholar 

  66. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279

    Article  PubMed  CAS  Google Scholar 

  67. Hers I, Vincent EE, Tavaré JM (2011) Akt signalling in health and disease. Cell Signal 23:1515–1527

    Article  PubMed  CAS  Google Scholar 

  68. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25:55–57

    Article  PubMed  CAS  Google Scholar 

  69. Sugimoto N, Miwa S, Tsuchiya H, Hitomi Y, Nakamura H, Yachie A, Koizumi S (2013) Targeted activation of PKA and EPAC promotes glioblastoma regression in vitro. Mol Clin Oncol 1(2):281–285

    Article  PubMed  PubMed Central  Google Scholar 

  70. Shchors K, Massaras A, Hanahan D (2015) Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cells-lethal autophagy and therapeutic Benefit. Cancer Cell 28(4):456–471

    Article  PubMed  CAS  Google Scholar 

  71. Malchinkhuu E, Sato K, Maehama T, Ishiuchi S, Yoshimoto Y, Mogi C, Kimura T, Kurose H, Tomura H, Okajima F (2009) Role of Rap1B and tumor suppressor PTEN in the negative regulation of lysophosphatidic acid-induced migration by isoproterenol in glioma cells. Mol Biol Cell 20(24):5156–5165

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Mostafavi H, Khaksarian M, Joghataei MT, Soleimani M, Hassanzadeh G, Eftekhari S, Soleimani M, Mousavizadeh K, Estiri H, Ahmadi S, Hadjighassem MR (2014) Selective β2 adrenergic agonist increases Cx43 and miR-451 expression via cAMP-EPAC. Mol Med Rep 9(6):2405–2410

    Article  PubMed  CAS  Google Scholar 

  73. Drell T, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70

    Article  PubMed  CAS  Google Scholar 

  74. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231–238

    Article  PubMed  CAS  Google Scholar 

  75. Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866–2869

    PubMed  CAS  Google Scholar 

  76. Bastian P, Balcarek A, Altanis C, Strell C, Niggemann B, Zaenker KS, Entschladen F (2009) The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett 274(2):218–224

    Article  PubMed  CAS  Google Scholar 

  77. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL (2003) Cyclic AMP induces integrin-mediated cell adhesion through EPAC and Rap1 upon stimulation of the beta 2-adrenergic receptor. J Cell Biol 160(4):487–493

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15

    Google Scholar 

  79. Teplinsky E, Muggia F (2015). EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res 4(1):107–117

    Google Scholar 

  80. Choi JH, Chen CL, Poon SL, Wang HS, Leung PC (2009) Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange prtein activated by cAMP pathway. Endocr Relat Cancer 16(1):179–188

    Article  PubMed  CAS  Google Scholar 

  81. Gao M, Ma Y, Bast RC Jr, Li Y, Wan L, Liu Y, Sun Y, Fang Z, Zhang L, Wang X, Wei Z (2016) EPAC1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Med Oncol 33(7):73

    Article  PubMed  CAS  Google Scholar 

  82. Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC (2003) The granulin-epithelin precursor/PC-cell-derived growth factor for epithelial ovarian cancer. Clin Cancer Res 9:44–51

    PubMed  CAS  Google Scholar 

  83. Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC (2005) Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP) prosurvival factor for ovarian cancer. Oncogene 24(47):7084–7089

    Article  PubMed  CAS  Google Scholar 

  84. Thaker PH, Han LY, Kamat AL, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939–944

    Article  PubMed  CAS  Google Scholar 

  85. Almahariq M, Mei FC, Cheng X (2016) The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. Acta Biochim Biophys Sin 48(1):75–81

    Article  PubMed  CAS  Google Scholar 

  86. Harper K, Arsenault D, Boulay-Jean S, Lauzier A, Lucien F, Dubois CM (2010) Autotaxin promotes cancer invasion via the Lysophosphatidic Acid Receptor 4: participation of the cyclic AMP/EPAC/Rac1 signalling pathway in invadopodia formation. Cancer Res 70:4634–4643

    Article  PubMed  CAS  Google Scholar 

  87. Baljinnyam E, Umemura M, De Lorenzo MS, Xie L-H, Nowycky M, Iwatsubo M, Chen S, Goydos JS, Iwatsubo K (2011) Gβγ subunits inhibit EPAC-induced melanoma cell migration. BMC Cancer 11:256

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Bastian P, Balcarek A, Altanis C et al (2009) The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett 274:218–224

    Article  PubMed  CAS  Google Scholar 

  89. Almahariq M, Tsalkova T, Mei FC, Chen H, Zhou J, Sastry SK (2013) A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol 83:122–128

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Almahariq M, Chao C, Mei FC, Hellmich MR, Patrikeev I, Motamedi M, Cheng X (2015) Pharmacological inhibition and genetic knockdown of exchange protein directly activated by cAMP 1 reduce pancreatic cancer metastasis in vivo. Mol Pharmacol 87(2):142–149

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ (2012) Role of JNK in mammary gland development and breast cancer. Can Res 72(2):472–481

    Article  CAS  Google Scholar 

  92. Hochbaum D, Tanos T, Ribeiro-Neto F, Altschuler D, Coso OA (2003) Activation of JNK by Epac is independent of its activity as a Rap guanine nucleotide exchanger. J Biol Chem 5(36):33738–33746

    Article  CAS  Google Scholar 

  93. Xiao L, Lan X, Shi X, Zhao K, Wang D, Wang X, Li F, Huang H, Liu J (2017) Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer. Cell Death Dis 8(5):e2803. https://doi.org/10.1038/cddis.2017.210

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Can Res 72(10):2457–2467. https://doi.org/10.1158/0008-5472.CAN-11-2612

    Article  CAS  Google Scholar 

  95. Overbeck AF, Brtva TR, Cox AD, Graham SM, Huff SY, Khosravi-Far R, Quilliam LA, Solski PA, Der CJ (1995) Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol Reprod Dev 42(4):468–476

    Article  PubMed  CAS  Google Scholar 

  96. Hammond SM, Altshuller YM, Sung TC, Rudge SA, Rose K, Engebrecht J, Morris AJ, Frohman MA (1995) Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J Biol Chem 270:29640–29643

    Article  PubMed  CAS  Google Scholar 

  97. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, Morris AJ, Frohman MA (1997) Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 7:191–201

    Article  PubMed  CAS  Google Scholar 

  98. López De Jesús M, Stope MB, Oude Weernink PA, Mahlke Y, Börgermann C, Ananaba VN, Rimmbach C, Rosskopf D, Michel MC, Jakobs KH, Schmidt M (2006) Cyclic AMP-dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to phospholipase D stimulation. J Biol Chem 281(31):21837–21847

    Article  CAS  Google Scholar 

  99. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 27(6892):949–954

    Article  CAS  Google Scholar 

  100. Dumaz N, Marais R (2005) Integrating signals between cAMP and RAS/MEK/ERK signaling pathways. FEBS J 272(14):3491–3504

    Article  PubMed  CAS  Google Scholar 

  101. Zhang S, Hui L, Li C, Gao J, Cui Z, Qiu X (2016) More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells. BMC Cancer 16:171. https://doi.org/10.1186/s12885-016-2218-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Thompson MA, Britt RD, Kuipers I, Stewart A, Thu J, Pandya HC, MacFarlane P, Pabelick CM, Martin RJ, Prakash YS (2015) cAMP-mediated secretion of brain-derived neurotrophic factor in developing airway smooth muscle. Biochim Biophys Acta 1853(10 0 0):2506–2514. https://doi.org/10.1016/j.bbamcr.2015.06.008

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Courilleau D, Bisserier M, Jullian JC, Lucas A, Bouyssou P, Fischmeister R, Blondeau JP, Lezoualc’h F (2012) Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP binding protein EPAC. J Biol Chem 287(53):44192–44202

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Tsalkova T, Mei FC, Li S, Chepurny OG, Leech CA, Liu T, Holz GG, Woods VL Jr. Cheng X (2012) Isoform-specific antagonists of exchange proteins directly activated by cAMP. Proc Natl Acad Sci USA 109(45):18613–18618

    Article  PubMed  PubMed Central  Google Scholar 

  105. Rehmann H (2013) Epac-inhibitors: facts and artefacts. Sci Rep 3:3032

    Article  PubMed  PubMed Central  Google Scholar 

  106. Chen H, Tsalkova T, Mei FC, Hu Y, Cheng X, Zhou J (2012) 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg Med Chem Lett 22(12):4038–4043

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Brown LM, Rogers KE, Aroonsakool N, McCammon JA, Insel PA (2014) Allosteric inhibition of EPAC: computational modeling and experimental validation to identify allosteric sites and inhibitors. J Biol Chem 42:29148–29157

    Article  CAS  Google Scholar 

  108. Rehmann H, Schwede F, Døskeland SO, Wittinghofer A, Bos JL (2003) Ligand-mediated activation of the cAMP-responsive guanine neucleotide exchange factor EPAC. J Biol Chem 278(40):38548–38556

    Article  PubMed  CAS  Google Scholar 

  109. Herbst KJ, Coltharp C, Amzel LM, Zhang J (2011) Direct activation of EPAC of Sulfonylurea is isoform selective. Chem Biol 18(2):243–251

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Zhang CL, Katoh M, Shibasaki T (2009) The cAMP sensor EPAC2 is a direct target of antidiabetic sulfonylurea drugs. Science 325(5940):607–610

    Article  PubMed  CAS  Google Scholar 

  111. Sheikh I, Koley H, Chakrabarti M, Hoque KM (2013) The EPAC signalling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrhoea. J Biol Chem 288(28):20404–20415

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Yokoyama U, Patel HH, Lai MC, Aroonsakool N, Roth DM, Insel PA (2008) The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. PNAS 105(17):6386–6391

    Article  PubMed  PubMed Central  Google Scholar 

  113. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S (2001) Critical role of cAMPGEFII–Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046–44653

    Article  PubMed  CAS  Google Scholar 

  114. Kang G, Chepurny OG, Holz GG (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536:375–385

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Chin EC, Abayasekara DR (2004) Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation. J Endocrinol 183:51–60

    Article  PubMed  CAS  Google Scholar 

  116. Li J, O’Connor KL, Cheng X, Mei FC, Uchida T, Townsend CM Jr, Evers BM (2007) Cyclic adenosine 5′-monophosphate-stimulated neurotensin secretion is mediated through Rap1 downstream of both Epac and protein kinase A signaling pathways. Mol Endocrinol 21:159–171

    Article  PubMed  CAS  Google Scholar 

  117. Branham MT, Mayorga LS, Tomes CN (2006) Calcium induced acrosomal exocytosis requires cAMP acting through a PKA-independent, EPAC-mediated pathway. J Biol Chem 281:8656–8666

    Article  PubMed  CAS  Google Scholar 

  118. Edland F, Wergeland A, Kopperud R, Åsrud KS, Hoivik EA, Witsø SL, Æsøy R, Madsen L, Kristiansen K, Bakke M, Døskeland SO, Jonassen AK (2016) Long term consumption of an obesogenic high fat diet prior to ischemia-reperfusion mediates cardioprotection via EPAC1-dependent signalling. Nutr Metabol 13:87

    Article  CAS  Google Scholar 

  119. Fujita T, Umemura M, Yokoyama U, Okumura S, Ishikawa Y (2017) The role of EPAC in the heart. Cell Mol Life Sci 74(4):591–606

    Article  PubMed  CAS  Google Scholar 

  120. Hunter JJ, Chien KR (1999) Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341:1276–1283

    Article  PubMed  CAS  Google Scholar 

  121. Schmidt M, Sand C, Jakobs KH, Michel MC, Weernink PA (2007) Epac and the cardiovascular system. Curr Opin Pharmacol 7:193–200

    Article  PubMed  CAS  Google Scholar 

  122. Gunning PW, Landreth GE, Bothwell MA, Shooter EM (1981) Differential and synergistic actions of nerve growth factor and cyclic AMP in PC12 cells. J Cell Biol 89:240–245

    Article  PubMed  CAS  Google Scholar 

  123. Williams IH, Polakis SE (1977) Differentiation of 3T3-L1 fibroblasts to adipocytes. The effect of indomethacin, prostaglandin E1 and cyclic AMP on the process of differentiation. Biochem Biophys Res Commun 77:175–186

    Article  PubMed  CAS  Google Scholar 

  124. Schmidt M, Dekker FJ, Maarsingh H (2013) Exchange protein directly activated by cAMP (EPAC): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev 65(2):670–709

    Article  PubMed  CAS  Google Scholar 

  125. Vang AG, Housley W, Dong H, Basole C, Ben-Sasson SZ, Kream BE, Epstein PM, Clark RB, Brocke S (2013). Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for EPAC. Biochem J 456(3):463–473

    Article  PubMed  CAS  Google Scholar 

  126. Momeny M, Sabourinejad Z, Zarrinrad G et al (2017) Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep 7:45954. https://doi.org/10.1038/srep45954

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Yu T, Tang B, Sun X (2017) Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy. Yonsei Med J 58(3):489–496. https://doi.org/10.3349/ymj.2017.58.3.489

    Article  PubMed  PubMed Central  Google Scholar 

  128. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 3:120. https://doi.org/10.3389/fonc.2013.00120

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

Seema Sehrawat is the recipient of Bio-CARe Award from Ministry of Science and Technology, Department of Biotechnology, Govt. of India, and acknowledges the funding support. Aaron Goldman is supported by the Breast Cancer Alliance Young Investigator Award, USA. Shiv Nadar Foundation is acknowledged for providing the PhD fellowship to Mr. Naveen Kumar and Mr. Peeyush Prasad. The funding agency had no role in design of the study, collection and analysis of the data, decision to publish, or manuscript preparation.

Author information

Author notes

  1. Naveen Kumar and Peeyush Prasad have contributed equally.

Authors and Affiliations

  1. Brain Metastasis and Neurovascular Disease Modeling Lab, Shiv Nadar University, NCR, India

    Naveen Kumar, Peeyush Prasad, Eshna Jash & Seema Sehrawat

  2. Medical Imaging Lab, Centre for Biomedical Engineering, IIT, Delhi, India

    Megha Saini

  3. School of Life and Allied Health Sciences, Glocal University, Saharanpur, India

    Amjad Husain

  4. Integrative Immuno-Oncology Center, Mitra Biotech, Woburn, MA, 01801, USA

    Aaron Goldman

  5. Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA

    Aaron Goldman & Seema Sehrawat

  6. Division of Engineering in Medicine, Brigham and Women’s Hospital, Boston, MA, 02115, USA

    Aaron Goldman

Authors
  1. Naveen Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peeyush Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eshna Jash
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megha Saini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amjad Husain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aaron Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seema Sehrawat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Aaron Goldman or Seema Sehrawat.

Ethics declarations

Conflict of interest

AG is an employee of Mitra Biotech and holds equity. All other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, N., Prasad, P., Jash, E. et al. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. Mol Cell Biochem 447, 77–92 (2018). https://doi.org/10.1007/s11010-018-3294-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-018-3294-z

Keywords

Search

Navigation